Lista de obras -

<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

artículo científico publicado en 2020

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia

artículo científico publicado en 2019

Analysis of the coding genome of diffuse large B-cell lymphoma

artículo científico publicado en 2011

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

artículo científico publicado en 2011

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

artículo científico publicado en 2013

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

artículo científico publicado en 2020

CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

artículo científico publicado en 2013

CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.

artículo científico publicado en 2009

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

artículo científico publicado en 2016

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

artículo científico publicado en 2016

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

artículo científico publicado en 2014

Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study

artículo científico publicado en 2006

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

artículo científico publicado en 2016

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

artículo científico publicado en 2013

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

artículo científico publicado en 2013

Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.

artículo científico publicado en 2012

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors

artículo científico publicado en 2011

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

artículo científico publicado en 2018

Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up

artículo científico publicado en 2014

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up

artículo científico publicado en 2011

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

artículo científico publicado en 2018

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

artículo científico publicado en 2016

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

artículo científico publicado en 2011

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma

artículo científico publicado en 2019

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases

scientific article published on 30 July 2018

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

artículo científico publicado en 2011

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

artículo científico publicado en 2012

Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?

artículo científico publicado en 2006

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival

artículo científico publicado en 2019

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

artículo científico publicado en 2017

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients

artículo científico publicado en 2016

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

artículo científico publicado en 2015

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

artículo científico publicado en 2017

Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia

scientific article published on 26 May 2017

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

artículo científico publicado en 2014

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.

artículo científico publicado en 2006

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

artículo científico publicado en 2017

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

artículo científico publicado en 2017

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

artículo científico publicado en 2015

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)

scientific article published on 21 February 2019

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

artículo científico publicado en 2018

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management

artículo científico publicado en 2013

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

artículo científico publicado en 2018

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

artículo científico publicado en 2015

Rare gastrointestinal lymphomas: The endoscopic investigation

artículo científico publicado en 2015

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

artículo científico publicado en 2014

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

artículo científico publicado en 2013

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

artículo científico publicado en 2013

Salvage therapy of multiple myeloma: the new generation drugs

artículo científico

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

artículo científico publicado en 2014

Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2010

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

artículo científico publicado en 2016

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

artículo científico publicado en 2018

Lista de obras de

<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia

Analysis of the coding genome of diffuse large B-cell lymphoma

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Rare gastrointestinal lymphomas: The endoscopic investigation

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

Salvage therapy of multiple myeloma: the new generation drugs

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.

Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab